Develop, manufacture, and sell genomic analysis oncology diagnostics
Medicare program policy for regulatory approval and reimbursement for new oncology diagnostic technologies 
Reimbursement for new oncology diagnostic technologies generally Food and Drug Administration regulatory policy generally and policy for approval of new oncology diagnostic technologies
S. 1895 (Lower Health Care Costs Act), Section 401, regarding hospital billing practices
H.R. 2328 (REACH Act), Title IV, regarding hospital billing practices
Reimbursement for new oncology diagnostic technologies generally, including public and private payers
H.R. 6102 (VALID Act of 2020), all provisions
MMM - Medicare/Medicaid HCR - Health Issues
ARENTFOX SCHIFF LLP
1717 K Street, NW, Washington, DC, 20006, US
DAN RENBERG OLIVER SPURGEON III DAN RENBERG OLIVER SPURGEON III